Table 1 Amicus Therapeutics, Inc. (a development stage company) Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share amounts) | |||||||||||
Period from | |||||||||||
February 4, 2002 | |||||||||||
(inception) | |||||||||||
Three Months | Six Months | to | |||||||||
Ended June 30, | Ended June 30, | June 30, | |||||||||
| 2009 | 2010 | 2009 | 2010 | 2010 | |||||||
| Revenue: | |||||||||||
Research revenue | $ 4,667 | $ - | $ 8,580 | $ - | $ 31,108 | ||||||
Collaboration revenue | 694 | - | 1,389 | - | 50,000 | ||||||
| Total revenue | 5,361 | - | 9,969 | - | 81,108 | ||||||
| Operating Expenses: | |||||||||||
Research and development | 13,470 | 8,137 | 25,345 | 17,026 | 192,748 | ||||||
General and administrative | 5,223 | 4,020 | 10,419 | 7,945 | 85,654 | ||||||
Restructuring charges | - | - | - | - | 1,522 | ||||||
Impairment of leasehold improvements | - | - | - | - | 1,030 | ||||||
Depreciation and amortization | 519 | 529 | 1,024 | 1,066 | 7,485 | ||||||
In-process research and development | - | - | - | - | 418 | ||||||
| Total operating expenses | 19,212 | 12,686 | 36,788 | 26,037 | 288,857 | ||||||
| Loss from operations | (13,851) | (12,686) | (26,819) | (26,037) | (207,749) | ||||||
| Other income (expenses): | |||||||||||
Interest income | 269 | 35 | 795 | 88 | 13,845 | ||||||
Interest expense | (41) | (55) | (71) | (137) | (2,063) | ||||||
Change in fair value of warrant liability | - | 1,391 | - | 1,595 | 1,141 | ||||||
Other expense | - | - | - | - | (1,116) | ||||||
| Loss before tax benefit | (13,623) | (11,315) | (26,095) | (24,491) | (195,942) | ||||||
Benefit from income taxes | - | - | - | - | 695 | ||||||
| Net loss | (13,623) | (11,315) | (26,095) | (24,491) | (195,247) | ||||||
Deemed dividend | - | - | - | - | (19,424) | ||||||
Preferred stock accretion | - | - | - | - | (802) | ||||||
Net loss attributable to common stockholders | $ (13,623) | $ (11,315) | $ (26,095) | $ (24,491) | $ (215,473) | ||||||
Net loss attributable to common stockholders per | |||||||||||
common share – basic and diluted | $ (0.60) | $ (0.41) | $ (1.15) | $ (0.94) | |||||||
Weighted-average common shares outstanding – | |||||||||||
basic and diluted | 22,618,026 | 27,623,297 | 22,615,951 | 25,956,366 | |||||||
